drug safety

pipeline pipes RD research
Biotech

Incyte scraps BET inhibitor and anti-CD122 drug

Incyte’s decision to scrap work on its BET inhibitor program has not surprised analysts, who pointed to safety concerns overshadowing the drug class.
James Waldron Oct 28, 2025 9:05am
two green lights

CytomX reports patient death from kidney injury in ADC trial

Aug 14, 2025 6:45am
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Jul 31, 2025 9:10am
sarepta building
Favicon Fierce Pharma

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm
FDA
Favicon Fierce Pharma

FDA eyeing study requirements to confirm Elevidys safety: report

Jul 24, 2025 3:12pm
Sarepta Sarepta Therapeutics
Favicon Fierce Pharma

Sarepta will continue shipping Elevidys despite FDA misgivings

Jul 21, 2025 10:42am